This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness. | MicrobiomeTrials
← Back to trials NCT07260773
The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness. Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07Est. Completion: 2027-03
Enrollment target: 128 participantsOther microbiome trials you might be interested in Endometrial Adenocarcinoma Endometrial Clear Cell Adenocarcinoma Endometrial Dedifferentiated Carcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Mucinous Adenocarcinoma Endometrial Undifferentiated Carcinoma Endometrioid Adenocarcinoma Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink t…
Birmingham, United States Est. completion Jul 30, 2032
Phase 3
Recruiting
Platinum Sensitive BRCA Mutated Relapsed Ovarian Cancer Following Complete or Partial Response to Platinum Based Chemotherapy
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib mainten…
Birmingham, United States Est. completion Sep 19, 2016
Advanced Malignant Solid Neoplasm Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Locally Advanced Malignant Solid Neoplasm Malignant Female Reproductive System Neoplasm Metastatic HER2-Negative Breast Carcinoma Metastatic Malignant Solid Neoplasm Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Malignant Female Reproductive System Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Unresectable HER2-Negative Breast Carcinoma Unresectable Malignant Solid Neoplasm
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment…
Birmingham, United States Est. completion Jul 1, 2030